What's MovingIngredientsFunding● Medium Urgency
⊙ Entrackr · Jul 16, 2026Reported
Scimplify's ₹181 Cr Series C is coming together at a 2X-plus markup, twelve months after its last round
Fact
An Entrackr exclusive, drawing on a board resolution, has the specialty chemicals platform assembling a ₹181 Cr Series C. Hitachi Ventures leads it, and the incumbent cap table is following on, 3one4 among them alongside Accel's India fund, Omnivore, and Bertelsmann's Dutch arm. That is a better-than-2X markup on a company that closed its Accel-led $40 Mn Series B only last August.
Interpretation
A 2X valuation jump inside twelve months, led by a Japanese industrial conglomerate's venture arm, is a statement about where the ingredient layer of Indian consumer products is heading. Scimplify sits one level below even the contract manufacturers: it supplies the specialty chemistry that goes into personal care formulations, flavours and actives. This week's capital map now runs the full stack, chemistry (Scimplify), manufacturing (Naturis, Edition 023; Groyyo, this edition), and the brand layer above them fighting for shelf space. The deepest layers are commanding the fastest markups, which is what a maturing consumer economy looks like from the inside.
Action
Beauty and wellness founders sourcing actives and specialty ingredients through importers: get a Scimplify quote into your next procurement cycle as a benchmark, because domestically-sourced specialty chemistry with fresh capital behind it is exactly where input-cost leverage appears first. If your differentiation claim is a hero ingredient, ask who else your supplier sells it to.
Watch Next
Formal close and final valuation, whether Hitachi's involvement signals Japanese demand for Indian specialty chemistry exports, and which consumer categories Scimplify prioritises next.